Report Finds High Costs For Pay-For-Delay Drugs

Law360, New York (July 16, 2013, 6:30 PM EDT) -- Reverse payment patent settlements have left U.S. consumers paying on average 10 times more for brand-name versions of key drugs used to treat everything from breast cancer to high cholesterol while waiting for generics to enter the market, according to a study released Thursday.

On average, so-called pay-for-delay settlements have held up the market entry of generic versions of blockbuster drugs for five years, according to a report published Thursday by public interest groups Community Catalyst and U.S. Public Interest Research Group.

The study is based...
To view the full article, register now.